Method: Different doses of α-enolase (10 and 100 µg) or immunodominant enolase peptide 1 from human [hEP1] or Porphyromonas gingivalis [pEP1] (1, 10 or 100µg) were intraperitoneally injected to 6 week-old DBA/1 mice one day prior to collagen II arthritis induction. Both clinical (weight, arthritis score, tarsal thickness) and biological (anti-collagen II and anti-α-enolase antibodies) were assessed during the 90 days follow-up period.
Result:Prophylactic injection of recombinant α-enolase was able to significantly prevent weight loss and to decrease the severity of arthritis evaluated by the arthritis score as well as the tarsal thickness. There was a dose-effect since 100 µg led to better results. Levels of anti-collagen II antibodies were significantly lower whereas titers of anti-α-enolase antibodies were significantly higher in mice treated with 100 µg of a-enolase compared to control mice. As regards to hEP1 and pEP1, we etablished a dose-dependant protective effect in CIA which is significant for pEP1. This protective effect is not due to once again a decrease of anti-collagen II antibodies titer.
Conclusion:Prophylactic treatment with recombinant α-enolase as well as immunodominant peptides has immunomodulatory effects in collagen-induced arthritis mice. The regulatory mechanisms induced by this protein seem to be partially due to a control of the production of anti-collagen II antibodies. Those results suggest that non-citrullinated α-enolase could constitute a potential new therapeutic approach in RA.
Disclosure: C. Guillou, None; G. Avenel, None; C. Derambure, None; M. Verdet, None; M. Hiron, None; M. Maho, None; X. Le Loët, None; S. Adriouch, None; O. Boyer, None; T. Lequerré, None; O. Vittecoq, None.